Anniko (penpulimab-kcqx)

P2, N=120, Not yet recruiting, West China Hospital

P=N/A, N=33, Recruiting, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College of Huazhong Universi

P2, N=51, Not yet recruiting, Hunan Cancer Hospital; Hunan Cancer Hospital

P2, N=59, Active, not recruiting, Sun Yat-sen University | N=110 --> 59 | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2024 --> Jul 2025 | Not yet recruiting --> Active, not recruiting

The present study aimed to establish a penpulimab-resistant model, delineate anti-PD-1 resistance traits via single-cell RNA sequencing, and unravel the precise mechanisms through which anlotinib-an anti-angiogenic agent-mitigates penpulimab resistance. Identifying Apoe⁺ M2 macrophages, Srgn⁺ M1 macrophages, and Cxcl2⁺ T cells provides key cellular and molecular targets for developing clinically actionable immunotherapies. Taken together, this work validates the preclinical potential of anlotinib combined with immunotherapy for immunotherapy-resistant tumors.

P2, N=65, Completed, Hunan Cancer Hospital | Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Jan 2025

P1/2, N=194, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=134 --> 194

Toripalimab and penpulimab significantly improve outcomes in RM-NPC. Their use is anticipated to expand into additional settings and malignancies as research matures.

Patients with a high TLS-to-tumor area ratio exhibited better survival. Our findings lay the groundwork for the feasibility of first-line de-escalated chemotherapy plus anlotinib and penpulimab in metastatic, persistent, or recurrent cervical cancer patients.

P1, N=22, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=34 --> 22 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Nov 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

P2, N=168, Recruiting, Peking University People's Hospital; Peking University People's Hospital

Compared with chemotherapy, except for ipilimumab+chemo [HR = 0.92,95%CI: (0.59-1.40)], atezolizumab+chemo [HR = 0.88, 95%CI: (0.56-1.40)], and durvalumab+chemo [HR = 0.84, 95% CI: (0.52-1.40)], durvalumab+ tremelimumab+chemo [HR = 0...Cemiplimab [HR = 0.48, 95% CI: (0.34-0.67)] showed the best OS benefit...Sugemalimab+chemo provided the best survival benefit [HR = 0.34, 95% CI: (0.24-0.48)]. For PD-L1≥50% tumors, penpulimab showed excellent OS and PFS; for PD-L1 1-49% tumors, pembrolizumab+chemo and camrelizumab+chemo achieved the best OS and PFS, respectively; for PD-L1≥1% tumors, the tislelizumab+chemo and camrelizumab+chemo showed the best OS and PFS results, while for tumors with PD-L1 <1%, both nivolumab and serplulimab+chemo provided significant survival benefit...Ipilimumab+chemo had the highest incidence of adverse events (AEs) &lsqb;OR = 2.0, 95% CI:(1.5-2.7)]. https://www.crd.york.ac.uk/prospero/, identifier CRD420251027447.